Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Commentary.

Urology practice·2026
Same author

From ChatGPT to UroGPT: A guideline-trained artificial intelligence model for male infertility.

Current urology·2026
Same author

Trends in Medicare utilization of intralesional collagenase injection and surgery for Peyronie's disease, 2013-2023.

The journal of sexual medicine·2026
Same author

Exploring the challenges and assistive technology for autistic job seekers across employment pathways.

Research in developmental disabilities·2025
Same author

Applying Data Science Practices to Identify Characteristics of Postsecondary Autism Support Programs From Their Websites.

Journal of autism and developmental disorders·2025
Same author

Futility indications in resuscitative thoracotomy: A retrospective observational study evaluating practice guidelines.

Injury·2025

Related Experiment Video

Updated: May 20, 2026

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

The translational imperative: making cell therapy simple and effective.

Glenn D Prestwich1, Isaac E Erickson, Thomas I Zarembinski

  • 1Department of Medicinal Chemistry and The Center for Therapeutic Biomaterials, The University of Utah, 419 Wakara Way, Suite 205, Salt Lake City, UT 84108-1257, USA. glenn.prestwich@hsc.utah.edu

Acta Biomaterialia
|July 11, 2012
PubMed
Summary

A novel hyaluronan-based scaffold, HyStem®, enhances cell therapy by improving cell delivery, retention, and growth. This injectable biomaterial shows promise in preclinical studies for vocal fold repair, heart function, liver regeneration, and stroke recovery.

More Related Videos

Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

Efficient and Rapid Generation of CAR-T and Cytokine-Induced Killer Cells in GMP-scalable Devices
09:30

Efficient and Rapid Generation of CAR-T and Cytokine-Induced Killer Cells in GMP-scalable Devices

Published on: December 5, 2025

Related Experiment Videos

Last Updated: May 20, 2026

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

Efficient and Rapid Generation of CAR-T and Cytokine-Induced Killer Cells in GMP-scalable Devices
09:30

Efficient and Rapid Generation of CAR-T and Cytokine-Induced Killer Cells in GMP-scalable Devices

Published on: December 5, 2025

Area of Science:

  • Biomaterials Science
  • Regenerative Medicine
  • Cell Therapy Engineering

Background:

  • Current cell therapy methods suffer from low cell retention and engraftment at administration sites, limiting therapeutic efficacy.
  • An injectable, biocompatible vehicle is crucial for effective cell delivery, retention, growth, and differentiation in cell-based therapies.
  • HyStem®, a hyaluronan-based semi-synthetic extracellular matrix (sECM), offers a customizable and clinically viable solution.

Purpose of the Study:

  • To evaluate the potential of HyStem® as an advanced delivery vehicle for various cell types in regenerative medicine.
  • To present preclinical evidence supporting HyStem®'s application in diverse therapeutic areas, including tissue repair and regeneration.
  • To discuss the practical challenges and considerations for the clinical translation of cell therapy combination products.

Main Methods:

  • Development of a customizable, hyaluronan-based semi-synthetic extracellular matrix (sECM) termed HyStem®.
  • Characterization of HyStem®'s ability to support diverse cell populations, including mesenchymal stem cells and pluripotent stem cells.
  • Preclinical testing of HyStem® in four distinct injury models: vocal fold repair, myocardial infarction, liver damage, and ischemic stroke.

Main Results:

  • HyStem® demonstrated capacity to support a wide range of therapeutic cells, from stem cells to mature cell populations from various tissues.
  • Preclinical studies indicated HyStem®'s potential in promoting tissue repair and functional recovery in vocal folds, heart, liver, and brain.
  • The sECM is manufacturable, approvable, and affordable, positioning it as a viable clinical product.

Conclusions:

  • HyStem® represents a significant advancement in cell therapy, offering an effective delivery and support system for therapeutic cells.
  • The preclinical data suggest broad applicability of HyStem® for regenerative medicine across multiple organ systems.
  • Addressing manufacturing, regulatory, and market challenges is essential for the successful clinical implementation of HyStem®-based cell therapies.